TEPEZZA
TEPEZZA (Teprotumumab-trbw) is an FDA-approved monoclonal antibody infusion therapy indicated for the treatment of thyroid eye disease (TED) in adult patients. Each 1×1 EA powder vial contains Teprotumumab, formulated for intravenous administration under professional supervision.
Teprotumumab works by inhibiting the insulin-like growth factor-1 receptor (IGF-1R), which plays a key role in the inflammatory and tissue remodeling processes associated with thyroid eye disease. This targeted therapy helps reduce eye bulging (proptosis), improve eye muscle function, and alleviate symptoms such as double vision and discomfort, offering patients a significant improvement in quality of life.
InfusionMed USA, headquartered in Carrollton, Texas, supplies TEPEZZA and other specialty neurology and ophthalmology infusion therapies to hospitals, clinics, and specialty infusion centers across Dallas, McKinney, Frisco, Plano, Lewisville, The Colony, and surrounding North Texas areas. We ensure cold-chain integrity, proper handling, and timely delivery for licensed healthcare providers.
For professional use only.
Download Form